Loading article…
Illumina director Keith Meister sold $57M in stock as the company prepares to rejoin the S&P 500 index on September 21, following a 66% year-to-date surge.
Illumina (ILMN) director Keith Meister sold $57.19 million in company shares between September 2 and September 4, even as the genomics firm prepares for its return to the S&P 500 index [1]. The transaction, which involved 263,560 shares sold at prices between $213 and $221.55, coincides with a period of significant volatility and growth for the stock, which has climbed 66.4% year-to-date [1].
| At a glance | |
|---|---|
| Insider Sale | $57.19 Million |
| YTD Stock Return | +66.4% |
| S&P 500 Inclusion Date | September 21 |
| Q2 2026 Revenue | $1.16 Billion |
The sale by Meister, executed through investment funds managed by Corvex Management, leaves him with 770,350 indirect shares and 6,780 direct shares [1]. While insider selling can reflect profit-taking or portfolio management, the company’s fundamental outlook has strengthened recently [1]. Illumina is scheduled to rejoin the S&P 500 before the market opens on September 21, replacing companies including Builders FirstSource and Molson Coors Beverage [1]. The inclusion is expected to drive demand for the stock as index-tracking funds adjust their holdings to match the benchmark [1].
Illumina’s return to the index follows a period of recovery; the stock was removed in June 2024 when it traded near $107, but it has since gained more than 100% to trade around $218 [1]. The company’s financial performance has been a primary driver of this trend, with Illumina beating earnings expectations in each of the past eight quarters [1]. In the second quarter of fiscal year 2026, the company reported $1.16 billion in revenue, exceeding the $1.13 billion consensus estimate [2].
The company’s growth is anchored by the NovaSeq X sequencing platform, which saw over 95 units placed in the second quarter of 2026 [2]. Beyond hardware, Illumina is expanding its role in AI-driven drug discovery through its Billion Cell Atlas alliance, which recently added partners like Formation Bio to help accelerate target validation for pharmaceutical firms [2]. This expansion has prompted several analysts to revise their outlooks, with JPMorgan Chase and Royal Bank of Canada both raising their price targets to $230 in late July 2026 [2].
Despite the positive momentum, the stock faces a "Very Negative" insider confidence signal according to TipRanks, with corporate insiders selling $436.7 million worth of shares over the past three months [1]. Current analyst consensus remains a "Moderate Buy," though the average price target of $197.44 suggests a potential 9.5% downside from recent trading levels [1].
Whether the index inclusion provides a sustained catalyst or if the heavy insider selling activity signals a ceiling for the stock remains the central question for investors. The company’s ability to maintain its streak of earnings beats will be tested as it integrates into the benchmark index.
Coverage is mostly measured — 268 of 290 reports stay neutral.
Every Monday — the token unlocks, Fed dates & catalysts set to move crypto and markets this week. So you’re never blindsided.
Free · 3-min read · one-click unsubscribe
AI-assisted synthesis by the TrendWatcher Editorial Desk · sourced from 2 outlets · Sep 8, 2026 · How we report
The S P 500 is a stock market index that tracks the performance of 500 large-capitalization companies listed on United States stock exchanges. It is maintained by S&P Dow Jones Indices and serves as a benchmark representing approximately 83% of the total market capitalization of U.S. public companies.
Companies are selected for the S P 500 by a committee based on specific criteria established for the S&P 1500 index. These criteria determine which large-capitalization stocks are included in the index.
Information Technology is the largest sector in the S P 500, comprising 37.4% of the index. Other significant sectors include Financials at 12.2% and Communication Services at 9.67%.
Investors can access products linked to the S P 500, such as index funds, exchange-traded funds, mutual funds, and derivatives like options and futures. These products are designed to replicate the performance of the S P 500 or provide modified risk/return profiles.